Prevalence of chronic pulmonary aspergillosis in patients with tuberculosis from Iran

  • M. T. Hedayati
  • Y. Azimi
  • A. Droudinia
  • B. Mousavi
  • A. Khalilian
  • N. Hedayati
  • D. W. Denning
Article

Abstract

In patients with preexisting lung disease, especially a cavity, Aspergillus can infect the surface of the cavity, causing chronic cavitary pulmonary aspergillosis (CCPA), and may form an aspergilloma, collectively called chronic pulmonary aspergillosis (CPA). In the present study, we assessed tuberculosis (TB) patients for CPA based on culture and serological methods. During a period of 1 year (from March 2013 to March 2014), we studied 124 patients with TB (94 with current TB and 30 with previous TB) at Masih Daneshvari Hospital in Tehran, Iran. Sputum specimens were analyzed by direct microscopic examination (DME) and fungal culture. The clinical and radiological features of all patients were recorded, to categorize the patients into CCPA and aspergilloma. All patients were screened for serum-specific IgG against A. fumigatus, by enzyme-linked immunosorbent assay (ELISA). Out of 124 patients with TB (66 male, age range: 10–91 years), 48 patients (38.7 %) exhibited residual cavities. Eighteen (14.5 %) patients had cavities with pleural thickening. A round-shaped mass lesion was detected in six patients (6.8 %). DME was positive in ten patients for septate fungal hyphae. A. fumigatus was grown from 14 samples. Fifty-five (44.3 %) cases were positive for serum-specific IgG against A. fumigatus. Of 124 patients with TB, 3 (2.4 %) met criteria for aspergilloma and 14 (11.3 %) for CCPA. CPA is a common clinical presentation in individuals with healed TB in Iran, as reported by previous studies from other countries.

References

  1. 1.
    Murray CJ, Ortblad KF, Guinovart C et al (2014) Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384(9947):1005–1070PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Dubaniewicz A, Trzonkowski P, Dubaniewicz-Wybieralska M, Dubaniewicz A, Singh M, Myśliwski A (2006) Comparative analysis of mycobacterial heat shock proteins-induced apoptosis of peripheral blood mononuclear cells in sarcoidosis and tuberculosis. J Clin Immunol 26(3):243–250CrossRefPubMedGoogle Scholar
  3. 3.
    Yan L, Cui H, Xiao H, Zhang Q (2013) Anergic pulmonary tuberculosis is associated with contraction of the Vd2+T cell population, apoptosis and enhanced inhibitory cytokine production. PLoS One 8(8):e71245PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Chen JC, Chang YL, Luh SP, Lee JM, Lee YC (1997) Surgical treatment for pulmonary aspergilloma: a 28 year experience. Thorax 52:810–813PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Denning DW, Riniotis K, Dobrashian R, Sambatakou H (2003) Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 37(Suppl 3):S265–S280CrossRefPubMedGoogle Scholar
  6. 6.
    Camuset J, Nunes H, Dombret MC et al (2007) Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 131:1435–1441CrossRefPubMedGoogle Scholar
  7. 7.
    Addrizzo-Harris DJ, Harkin TJ, McGuinness G, Naidich DP, Rom WN (1997) Pulmonary aspergilloma and AIDS. A comparison of HIV-infected and HIV-negative individuals. Chest 111:612–618CrossRefPubMedGoogle Scholar
  8. 8.
    Smith NL, Denning DW (2011) Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 37(4):865–872CrossRefPubMedGoogle Scholar
  9. 9.
    Kosmidis C, Denning DW (2015) The clinical spectrum of pulmonary aspergillosis. Thorax 70(3):270–277CrossRefPubMedGoogle Scholar
  10. 10.
    Ma JE, Yun EY, Kim YE et al (2011) Endobronchial aspergilloma: report of 10 cases and literature review. Yonsei Med J 52(5):787–792PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Kurhade AM, Deshmukh JM, Fule RP, Chande C, Akulwar S (2002) Mycological and serological study of pulmonary aspergillosis in central India. Indian J Med Microbiol 20(3):141–144PubMedGoogle Scholar
  12. 12.
    Shahid M, Malik A, Bhargava R (2001) Prevalence of Aspergillosis in chronic lung diseases. Indian J Med Microbiol 19(4):201–205PubMedGoogle Scholar
  13. 13.
    Sakarya ME, Özbay B, Yalcinkaya I, Arsalan H, Uzun K, Poykaz N (1998) Aspergillomas in the lung cavities. East J Med 3(1):7–9Google Scholar
  14. 14.
    Ferreira-Da-Cruz MF, Wanke B, Pirmez C, Galvão-Castro B (1988) Aspergillus fumigatus fungus ball in hospitalized patients with chronic pulmonary disease. Usefulness of double immunodiffusion test as a screening procedure. Mem Inst Oswaldo Cruz 83:357–360CrossRefPubMedGoogle Scholar
  15. 15.
    Iwata H, Miwa T, Takagi K (1990) Tuberculosis sequelae: secondary fungal infections. Kekkaku 65:867–871PubMedGoogle Scholar
  16. 16.
    Raper KB, Fennell DI (1973) The genus Aspergillus. Robert E. Krieger Publishing Company, New YorkGoogle Scholar
  17. 17.
    Hope WW, Walsh TJ, Denning DW (2005) The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 43:S207–S238CrossRefPubMedGoogle Scholar
  18. 18.
    Saraceno JL, Phelps DT, Ferro TJ, Futerfas R, Schwartz DB (1997) Chronic necrotizing pulmonary aspergillosis: approach to management. Chest 112:541–548CrossRefPubMedGoogle Scholar
  19. 19.
    Al-Shair K, Atherton GT, Harris C, Ratcliffe L, Newton PJ, Denning DW (2013) Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis. Clin Infect Dis 57(6):828–835PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Biswas D, Agarwal S, Sindhwani G, Rawat J (2010) Fungal colonization in patients with chronic respiratory diseases from Himalayan region of India. Ann Clin Microbiol Antimicrob 9:28–35PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Sivasankari S, Senthamarai S, Anitha C et al (2014) Prevalence of invasive aspergillosis among (PTB) patients in Kanchipuram, India. J Clin Diagn Res 8(3):22–23Google Scholar
  22. 22.
    Shirai M, Hayakawa H, Uchiyama H, Chida K, Nakamura H (2001) Clinical significance of potential pathogenic microorganisms of sputum in patients with pulmonary tuberculosis. Respirology 6(4):311–315CrossRefPubMedGoogle Scholar
  23. 23.
    Salek Moghaddam A, Soltani Arabshahi SK, Yasami A, Tabatabaie S (2001) Survey of humoral immunity against Aspergillus fumigatus in patients with TB and COPD referred to Iran university hospitals. Pejouhesh 25(3):143–147Google Scholar
  24. 24.
    Nakamoto K, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y (2013) Prognostic factors in 194 patients with chronic necrotizing pulmonary aspergillosis. Intern Med 52(7):727–734CrossRefPubMedGoogle Scholar
  25. 25.
    Ohba H, Miwa S, Shirai M et al (2012) Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir Med 106(5):724–729CrossRefPubMedGoogle Scholar
  26. 26.
    Uffredi ML, Mangiapan G, Cadranel J, Kac G (2003) Significance of Aspergillus fumigatus isolation from respiratory specimens of nongranulocytopenic patients. Eur J Clin Microbiol Infect Dis 22(8):457–462CrossRefPubMedGoogle Scholar
  27. 27.
    Kitasato Y, Tao Y, Hoshino T et al (2009) Comparison of Aspergillus galactomannan antigen testing with a new cut-off index and Aspergillus precipitating antibody testing for the diagnosis of chronic pulmonary aspergillosis. Respirology 14(5):701–708CrossRefPubMedGoogle Scholar
  28. 28.
    Fraczek MG, Kirwan MB, Moore CB, Morris J, Denning DW, Richardson MD (2014) Volume dependency for culture of fungi from respiratory secretions and increased sensitivity of Aspergillus quantitative PCR. Mycoses 57:69–78CrossRefPubMedGoogle Scholar
  29. 29.
    Jin E, Wang LM, Li QY, Feng X, Ma SL (2014) Chronic necrotizing pulmonary aspergillosis in an immunocompetent patient: report of a rare case. Infection 42(3):565–568CrossRefPubMedGoogle Scholar
  30. 30.
    Tashiro T, Izumikawa K, Tashiro M et al (2013) A case series of chronic necrotizing pulmonary aspergillosis and a new proposal. Jpn J Infect Dis 66(4):312–316CrossRefPubMedGoogle Scholar
  31. 31.
    Pendleton M, Denning DW (2012) Multifocal pulmonary aspergillomas: case series and review. Ann N Y Acad Sci 1272:58–67CrossRefPubMedGoogle Scholar
  32. 32.
    Denning DW, Pleuvry A, Cole DC (2011) Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ 89:864–872PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    [No authors listed] (1968) Aspergillus in persistent lung cavities after tuberculosis. A report from the Research Committee of the British Tuberculosis Association. Tubercle 49:1–11CrossRefGoogle Scholar
  34. 34.
    [No authors listed] (1970) Aspergilloma and residual tuberculous cavities—the results of a resurvey. Tubercle 51:227–245CrossRefGoogle Scholar
  35. 35.
    Pena TA, Soubani AO, Samavati L (2011) Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature. Lung 189(2):167–172CrossRefPubMedGoogle Scholar
  36. 36.
    Schweer KE, Bangard C, Hekmat K, Cornely OA (2014) Chronic pulmonary aspergillosis. Mycoses 57(5):257–270CrossRefPubMedGoogle Scholar
  37. 37.
    Vahid B, Marik P (2007) Fatal massive hemoptysis in a patient on low-dose oral prednisone: chronic necrotizing pulmonary aspergillosis. Respir Care 52:56–58PubMedGoogle Scholar
  38. 38.
    Kokkonouzis I, Athanasopoulos I, Doulgerakis N et al (2011) Fatal hemoptysis due to chronic cavitary pulmonary aspergillosis complicated by nontuberculous mycobacterial tuberculosis. Case Rep Infect Dis 2011:837146PubMedCentralPubMedGoogle Scholar
  39. 39.
    Agarwal R, Vishwanath G, Aggarwal AN, Garg M, Gupta D, Chakrabarti A (2013) Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. Mycoses 56(5):559–570CrossRefPubMedGoogle Scholar
  40. 40.
    Cadranel J, Philippe B, Hennequin C et al (2012) Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol Infect Dis 31(11):3231–3239PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Jain LR, Denning DW (2006) The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect 52:e133–e137CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • M. T. Hedayati
    • 1
    • 2
  • Y. Azimi
    • 1
    • 2
  • A. Droudinia
    • 3
  • B. Mousavi
    • 1
    • 2
  • A. Khalilian
    • 4
  • N. Hedayati
    • 5
  • D. W. Denning
    • 6
    • 7
  1. 1.Invasive Fungi Research CenterMazandaran University of Medical SciencesSariIran
  2. 2.Department of Medical Mycology and ParasitologyMazandaran University of Medical SciencesSariIran
  3. 3.Transplantation Research Center, National Research Institute for Tuberculosis and Lung Disease, Masih Daneshvari HospitalShaheed Beheshti University of Medical ScienceTehranIran
  4. 4.Department of Statistics, School of MedicineMazandaran University of Medical ScienceSariIran
  5. 5.Ramsar International BranchMazandaran University of Medical SciencesSariIran
  6. 6.The National Aspergillosis Centre, University Hospital of South ManchesterUniversity of ManchesterManchesterUK
  7. 7.Academic Health Science CentreManchesterUK

Personalised recommendations